Elizabeth Prechtel-Dunphy on the Shortage of Oncology Nurses

Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Adagrasib vs Sotorasib: How Do They Compare for Patients With KRAS G12C– Mutated NSCLC?

Podcast

In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.

Linda Childers

Should You Wait for NGS Results Before Initiating NSCLC Treatment?

New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.

Is It Time to Rethink the Bell Ringing Ceremony in Cancer Care?

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML

Lindsey Zinck, PhD, RN, OCN, NEA-BC, and Melania Zisa, RN, BSN, OCN, discuss why it may be time to make the bell ringing ceremony a more inclusive celebration in cancer care.

Jordyn Sava

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia.

Related Content

Michelle Kirschner, RN, MSN, ACNP, APRN-BC

Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Adagrasib vs Sotorasib: How Do They Compare for Patients With KRAS G12C– Mutated NSCLC?

Podcast

Linda Childers

Should You Wait for NGS Results Before Initiating NSCLC Treatment?

New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.

Is It Time to Rethink the Bell Ringing Ceremony in Cancer Care?

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML

Lindsey Zinck, PhD, RN, OCN, NEA-BC, and Melania Zisa, RN, BSN, OCN, discuss why it may be time to make the bell ringing ceremony a more inclusive celebration in cancer care.

Jordyn Sava